Sami Labs Ltd., the Bangalore-based herbal drug major, is all set for a major thrust into formulations activity with focus on important cities of the country. The company will add 12 new products to its current product list, envisaging the impetus.
According to the plan, the company will introduce a package of 20-25 products including 12 new products, within April 2006. The thrust, which has been under planning from November, this year, will trigger operations by January 2006. The product range will be increased with more new innovative products gradually, from the current target of 25 products, after April 2006.
"We are focussing on major cities as our market. The first round strategy analysis has been completed, and the operation will be a much focussed one," Dr. Muhammed Majeed, chairman and managing director, Sami Labs told Pharmabiz.
Sami Labs is also planning to introduce a herbal drug for cystic fibrosis, in collaboration with a French company. Though refused to reveal the name of the company, Dr. Majeed said that the French company would commence clinical study by the month of January 2006, while the preliminary screening of the product has been conducted by Samil Labs.
The Rs 259 crore Sami Labs is waiting for drug approval for two of its products from the Drugs Control General of India. The company is in the final stage submission of data for the drug against Glaucoma. The company is awaiting an approval for a product for psoriasis from DCGI, informed Dr. Majeed.